US FDA inspects Granules India facility

Triggered by one of the firm's ANDAs, the inspection concluded with no observations

The stock price of Hyderabad-based Aurobindo Pharma and Granules India Limited today appreciated by as much as 4.18 per cent and 3.43 per cent respectively on the Bombay Stock Exchange (BSE) in the light of the reports that their manufacturing units were inspected by the US FDA in connection with some new drug applications.

While Granules India has informed the stock exchanges that the US FDA had inspected one of its facility last week and the inspection concluded with no observations, rumours about a similar inspection with regard to Aurobindo also surfaced on Monday. However, an Aurobindo spokesperson did not respond to confirm or deny this development.

Granules said the inspection was triggered by one of its abbreviated new drug application  (ANDA).

Aurobindo scrip was up by Rs 47.95 at Rs 1,194.65 while Granules India shares were Rs 30.10 higher than the previous close at Rs 908.70 on Monday.